Statistiques de base
| CIK | 1401923 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Harbor ETF Trust - Harbor Multi-Asset Explorer ETF
SEC Filings (Chronological Order)
Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.
| February 7, 2014 |
MAPP / Map Pharmaceuticals, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 mapp.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 5 Name of Issuer: MAP Pharmaceuticals, Inc. Title of Class of Securities: Common Stock CUSIP Number: 56509R108 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROU |
|
| March 11, 2013 |
- POST-EFFECTIVE AMENDMENT NO. 1 POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on March 11, 2013 Registration No. 333-164894 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAP PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-050704 |
|
| March 11, 2013 |
- POST-EFFECTIVE AMENDMENT NO. 1 POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on March 11, 2013. Registration No. 333-158253 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAP PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-05070 |
|
| March 11, 2013 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-33719 MAP Pharmaceuticals, Inc. (Exact name of registrant as spec |
|
| March 11, 2013 |
- POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on March 11, 2013. Registration No. 333-146656 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAP PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-0507047 (State or other jurisdiction |
|
| March 11, 2013 |
- POST-EFFECTIVE AMENDMENT NO. 1 POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on March 11, 2013. Registration No. 333-165694 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAP PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-05070 |
|
| March 11, 2013 |
- POST-EFFECTIVE AMENDMENT NO. 1 POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on March 11, 2013. Registration No. 333-174024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAP PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-05070 |
|
| March 11, 2013 |
- POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on March 11, 2013 Registration No. |
|
| March 11, 2013 |
- POST-EFFECTIVE AMENDMENT NO. 1 POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on March 11, 2013 Registration No. 333-182976 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAP PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-050704 |
|
| March 11, 2013 |
- POST-EFFECTIVE AMENDMENT NO. 1 POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on March 11, 2013. Registration No. 333-181284 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAP PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-05070 |
|
| March 5, 2013 |
MAPP / Map Pharmaceuticals, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) MAP Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 56509R108 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to |
|
| March 1, 2013 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION MAP PHARMACEUTICALS, INC. EX-3.1 2 d495160dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MAP PHARMACEUTICALS, INC. FIRST: The name of the corporation (hereinafter the “Corporation”) is: MAP Pharmaceuticals, Inc. SECOND: The name and address, including street, number, city and county, of the registered agent of the Corporation in the State of Delaware are: Corporation Service Company 2711 |
|
| March 1, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 3) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 MAP PHARMACEUTICALS, INC. (Name of Subject Company) MAP PHARMACEUTICALS, INC. (Names of Person(s) Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities) 56509R10 |
|
| March 1, 2013 |
EX-99.(a)(5)(E) Exhibit (a)(5)(E) ALLERGAN, INC. ANNOUNCES EXPIRATION OF TENDER OFFER FOR ALL OUTSTANDING SHARES OF MAP PHARMACEUTICALS, INC. AND INTENT TO EXERCISE TOP-UP OPTION TO EFFECT A SHORT-FORM MERGER March 1, 2013 (Irvine, CA) — Allergan, Inc. (NYSE: AGN) (“Allergan”) today announced the expiration of the tender offer (the “Offer”) initiated by its wholly-owned subsidiary, Groundhog Acqui |
|
| March 1, 2013 |
MAPP / Map Pharmaceuticals, Inc. / ALLERGAN INC - AMENDMENT NO. 2 TO SCHEDULE TO SC TO-T/A 1 d494450dsctota.htm AMENDMENT NO. 2 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) MAP PHARMACEUTICALS, INC. (Name of Subject Company — Issuer) GROUNDHOG ACQUISITION, INC. ALLERGAN, INC. (Names of Filing Persons — Offerors |
|
| March 1, 2013 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MAP PHARMACEUTICALS, INC., a Delaware corporation TABLE OF CONTENTS Page No. ARTICLE I. OFFICES 1 Section 1.1 Registered Office. 1 Section 1.2 Other Offices. 1 ARTICLE II. MEETINGS OF STOCKHOLDERS 1 Section 2.1 Place of Meetings. 1 Section 2.2 Annual Meeting of Stockholders. 1 Section 2.3 Quorum; Adjourned Meetings and Notice Thereof. 1 Section 2.4 |
|
| March 1, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2013 MAP PHARMACEUTICALS, INC. |
|
| February 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MAP PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 56509R108 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sched |
|
| February 11, 2013 |
MAPP / Map Pharmaceuticals, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 3 Name of Issuer: MAP Pharmaceuticals, Inc. Title of Class of Securities: Common Stock CUSIP Number: 56509R108 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b) N/A 3 |
|
| February 11, 2013 |
MAPP / Map Pharmaceuticals, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 8, 2013 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 2) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 MAP PHARMACEUTICALS, INC. (Name of Subject Company) MAP PHARMACEUTICALS, INC. (Names of Person(s) Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities |
|
| February 8, 2013 |
Exhibit (a)(5)(D) EX (a)(5)(D) ALLERGAN, INC. AND MAP PHARMAECUTIACALS, INC. ANNOUNCE THE FEDERAL TRADE COMMISSION HAS GRANTED EARLY TERMINATION OF WAITING PERIOD UNDER HART-SCOTT-RODINO ACT February 7, 2013 (Irvine, CA and Mountain View, CA) — Allergan, Inc. (NYSE: AGN) (“Allergan”) and MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) (“MAP”) today announced that the Federal Trade Commission has granted |
|
| February 8, 2013 |
- AMENDMENT NO. 1 TO SCHEDULE TO-T Amendment No. 1 to Schedule TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) MAP PHARMACEUTICALS, INC. (Name of Subject Company — Issuer)) GROUNDHOG ACQUISITION, INC. ALLERGAN, INC. (Names of Filing Persons — Offerors) Common Stock, par value $0 |
|
| February 7, 2013 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 MAP PHARMACEUTICALS, INC. (Name of Subject Company) MAP PHARMACEUTICALS, INC. (Names of Person(s) Filing Statement) Common Stock, $0.01 par value per share (Title of Class of Securities |
|
| January 31, 2013 |
Offer to Purchase Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of MAP Pharmaceuticals, Inc. |
|
| January 31, 2013 |
Letter to Stockholders Exhibit (a)(5) January 31, 2013 Dear Stockholder: We are pleased to inform you that on January 22, 2013, MAP Pharmaceuticals, Inc. |
|
| January 31, 2013 |
Letter to Clients Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of MAP Pharmaceuticals, Inc. |
|
| January 31, 2013 |
Notice of Guaranteed Delivery Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of MAP Pharmaceuticals, Inc. |
|
| January 31, 2013 |
EX-99.(E)(10) 3 d473134dex99e10.htm CONFIDENTIALITY AGREEMENT Exhibit(e)(10) December 17, 2012 Allergan, Inc. 2525 Dupont Drive Irvine, CA 92612-1599 Attention: David M. Lawrence Re: Confidentiality Agreement Ladies and Gentlemen: In connection with your consideration of a possible transaction with or involving (a “Possible Transaction”) MAP Pharmaceuticals, Inc. and/or its subsidiaries, affiliate |
|
| January 31, 2013 |
Letter of Transmittal and Form W-9 Exhibit(a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of MAP Pharmaceuticals, Inc. |
|
| January 31, 2013 |
Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 MAP PHARMACEUTICALS, INC. (Name of Subject Company—Issuer) GROUNDHOG ACQUISITION, INC. ALLERGAN, INC. (Names of Filing Persons—Offerors) Common Stock, par value $0.01 per share (Title of Class of Securities) |
|
| January 31, 2013 |
Schedule 14D-9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 31, 2013 |
Letter to Brokers Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of MAP Pharmaceuticals, Inc. |
|
| January 31, 2013 |
EX-99.(A)(1)(F) 7 d474701dex99a1f.htm SUMMARY ADVERTISEMENT Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase dated January 31, 2013 and the related Letter of Transmittal and any amendments or supplements thereto. Purchaser (as defined below) is n |
|
| January 31, 2013 |
ALLERGAN COMMENCES CASH TENDER OFFER FOR ALL OUTSTANDING SHARES OF MAP PHARMACEUTICALS Press Release Exhibit (a)(5)(C) ALLERGAN COMMENCES CASH TENDER OFFER FOR ALL OUTSTANDING SHARES OF MAP PHARMACEUTICALS January 31, 2013 (Irvine, CA) - Allergan, Inc. |
|
| January 30, 2013 |
MAPP / Map Pharmaceuticals, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 MAP Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 56509R108 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices an |
|
| January 30, 2013 |
Termination of a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2013 MAP PHARMACEUTICALS, INC. |
|
| January 29, 2013 |
MAPP / Map Pharmaceuticals, Inc. / ALLERGAN INC - SCHEDULE 13D Activist Investment SC 13D 1 d475430dsc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D [Rule 13d-101] INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. )* MAP Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 |
|
| January 29, 2013 |
Exhibit 1 Exhibit 1 JOINT FILNG AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, Allergan, Inc. |
|
| January 24, 2013 |
Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 MAP PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) GROUNDHOG ACQUISITION, INC. A wholly owned subsidiary of ALLERGAN, INC. (Names of Filing Persons (identifying status as offeror, issuer or other p |
|
| January 24, 2013 |
Exhibit 99.1 Exhibit 99.1 Allergan, Inc. AGN Acquisition of MAP Pharmaceuticals, Inc by Allergan, Inc Call Jan. 23, 2013 Company p Ticker p Event Type p Date p PARTICIPANTS Corporate Participants Joann Bradley – Head-Investor Relations David E. I. Pyott – Chairman, President & Chief Executive Officer Jeffrey L. Edwards – Chief Financial Officer & EVP Finance & Business Development Scott M. Whitcup |
|
| January 23, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2013 MAP PHARMACEUTICALS, INC. |
|
| January 23, 2013 |
EXHIBIT 99.1 Exhibit 99.1 Execution Version TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT, dated as of January 22, 2013 (this “Agreement”), is made among Allergan, Inc., a Delaware corporation (“Parent”), Groundhog Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and each of the individuals or entities listed on a signature page here |
|
| January 23, 2013 |
Tender and Support Agreement Exhibit 10.1 Execution Version TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT, dated as of January 22, 2013 (this “Agreement”), is made among Allergan, Inc., a Delaware corporation (“Parent”), Groundhog Acquisition, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and each of the individuals or entities listed on a sig |
|
| January 23, 2013 |
EXHIBIT 99.2 Exhibit 99.2 ALLERGAN, INC. TO ACQUIRE MAP PHARMACEUTICALS, INC. Acquisition Enhances Allergan Leadership Position in Neurology and Migraine Specialty January 22, 2013 (Irvine, CA and Mountain View, CA) — Allergan, Inc. (NYSE:AGN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today jointly announced that they have entered into a definitive merger agreement whereby Allergan will acquire |
|
| January 23, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 22, 2013 Date of Report (Date of earliest event reported) ALLERGAN, INC. (Exact name of registrant as specified in its charter) Delaware 1-10269 95-1622442 (State of Incorporation) (Commission File Number) (I.R.S. Em |
|
| January 23, 2013 |
Agreement and Plan of Merger Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among Allergan, Inc., Groundhog Acquisition, Inc. and MAP Pharmaceuticals, Inc. Dated as of January 22, 2013 TABLE OF CONTENTS Page ARTICLE 1 THE OFFER AND THE MERGER 2 1.1 The Offer 2 1.2 Company Actions 4 1.3 Directors 5 1.4 The Merger 6 1.5 Closing and Effective Time of the Merger 7 1.6 Meeting of Stockholde |
|
| January 23, 2013 |
EXHIBIT 2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER among Allergan, Inc., Groundhog Acquisition, Inc. and MAP Pharmaceuticals, Inc. Dated as of January 22, 2013 TABLE OF CONTENTS Page ARTICLE 1 THE OFFER AND THE MERGER 2 1.1 The Offer 2 1.2 Company Actions 4 1.3 Directors 5 1.4 The Merger 6 1.5 Closing and Effective Time of the Merger 7 1.6 Meeting of Stockholders to Approve the |
|
| January 23, 2013 |
EX-99.1 4 d474416dex991.htm PRESS RELEASE Exhibit 99.1 ALLERGAN, INC. TO ACQUIRE MAP PHARMACEUTICALS, INC. Acquisition Enhances Allergan Leadership Position in Neurology and Migraine Specialty January 22, 2013 (Irvine, CA and Mountain View, CA) — Allergan, Inc. (NYSE:AGN) and MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today jointly announced that they have entered into a definitive merger agreement |
|
| January 23, 2013 |
Schedule 14D-9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 MAP PHARMACEUTICALS, INC. (Name of Subject Company) MAP PHARMACEUTICALS, INC. (Name of Person Filing Statement) Common Stock, par value $0.01 per share (Title of Class of Securities) |
|
| November 21, 2012 |
MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA Resubmission for LEVADEX® -New PDUFA date April 15, 2013- MOUNTAIN VIEW, Calif. |
|
| November 21, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2012 MAP PHARMACEUTICALS, INC. |
|
| November 6, 2012 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 1, 2012 |
MAP Pharmaceuticals Reports Third Quarter of 2012 Financial Results MAP Pharmaceuticals Reports Third Quarter of 2012 Financial Results MOUNTAIN VIEW, Calif. |
|
| November 1, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2012 MAP PHARMACEUTICALS, INC. |
|
| October 16, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2012 MAP PHARMACEUTICALS, INC. |
|
| October 16, 2012 |
MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug MOUNTAIN VIEW, Calif. |
|
| August 29, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2012 MAP PHARMACEUTICALS, INC. |
|
| August 29, 2012 |
Press Release Exhibit 99.1 FOR IMMEDIATE DISTRIBUTION MAP Pharmaceuticals, Inc. Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares of Common Stock MOUNTAIN VIEW, Calif., August 29, 2012 /PRNewswire via COMTEX News Network/ — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the underwriter of its recent public offering of common stock fully exercised its opti |
|
| August 2, 2012 |
3,880,598 Shares MAP Pharmaceuticals, Inc. Common Stock PROSPECTUS SUPPLEMENT Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. |
|
| August 1, 2012 |
S-3MEF 1 d388036ds3mef.htm FORM S-3MEF As filed with the Securities and Exchange Commission on August 1, 2012 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MAP PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 20-0507047 (State or other jurisdiction o |
|
| August 1, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2012 MAP PHARMACEUTICALS, INC. |
|
| August 1, 2012 |
FOR IMMEDIATE DISTRIBUTION MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock Press Release Exhibit 99.1 FOR IMMEDIATE DISTRIBUTION MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock MOUNTAIN VIEW, Calif., August 1, 2012 /PRNewswire via COMTEX News Network/ — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the pricing of an underwritten public offering of 3,880,598 shares of its common stock at a price of $13.40 per share to the public. All of the sha |
|
| August 1, 2012 |
- FORM OF UNDERWRITING AGREEMENT Form of underwriting agreement Exhibit 1.1 [ ] Shares of Common Stock par value $0.01 MAP PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT August 1, 2012 Merrill Lynch, Pierce, Fenner & Smith Incorporated as Representative of the several Underwriters c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Ladies and Gentlemen: 1. INTRODUCTION. MAP Pharmaceutical |
|
| July 31, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2012 MAP PHARMACEUTICALS, INC. |
|
| July 31, 2012 |
Press Release Exhibit 99.1 FOR IMMEDIATE DISTRIBUTION MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock MOUNTAIN VIEW, Calif., July 31, 2012 /PRNewswire via COMTEX News Network/ — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. MAP Pharmaceuticals expects to grant th |
|
| July 31, 2012 |
Preliminary Prospectus Supplement Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| July 27, 2012 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 24, 2012 |
MAP Pharmaceuticals Reports Second Quarter of 2012 Financial Results MAP Pharmaceuticals Reports Second Quarter of 2012 Financial Results MOUNTAIN VIEW, Calif. |
|
| July 24, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 v3193118k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2012 MAP PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33719 20-0507047 (State or Other Jurisdict |
|
| June 25, 2012 |
Press Release Exhibit 99.1 MAP Pharmaceuticals Provides Update Following Meeting with FDA for LEVADEX® (dihydroergotamine) New Drug Application — Company plans to resubmit in late Q3/early Q4 2012 — MOUNTAIN VIEW, Calif., June 25, 2012 /PRNewswire/ — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the Company completed an End-of-Review meeting with the United States Food and Drug Adm |
|
| June 25, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2012 MAP PHARMACEUTICALS, INC. |
|
| May 18, 2012 |
Submission of Matters to a Vote of Security Holders 8-K 1 d355893d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2012 MAP PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33719 20-0507047 (State or Other Jurisdiction of |
|
| May 9, 2012 |
Form S-8 As filed with the Securities and Exchange Commission on May 9, 2012 Registration No. |
|
| May 8, 2012 |
Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 4, 2012 |
MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results MAP Pharmaceuticals Reports First Quarter of 2012 Financial Results MOUNTAIN VIEW, Calif. |
|
| May 4, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2012 MAP PHARMACEUTICALS, INC. |
|
| April 16, 2012 |
Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 12, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2012 MAP PHARMACEUTICALS, INC. |
|
| April 12, 2012 |
MAP Pharmaceuticals Provides Update on LEVADEX Press Release Exhibit 99.1 MAP Pharmaceuticals Provides Update on LEVADEX® Program MOUNTAIN VIEW, Calif., April 12, 2012 /PRNewswire/ — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today provided an update on LEVADEX®, the Company’s investigational orally inhaled drug for the potential acute treatment of migraine in adults. • The Company submitted a request to the U.S. Food and Drug Administration (FD |
|
| March 30, 2012 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT First Amendment to Employment Agreement Exhibit 10.41 EXECUTION COPY FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to the Employment Agreement, dated February 6, 2012, is entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Thomas A. Armer, Ph.D (“Executive”). WHEREAS, Executive and the Company entered into that certain Employment Agreement |
|
| March 30, 2012 |
FOIA Confidential Treatment FOIA CONFIDENTIAL TREATMENT REQUESTED BY MAP PHARMACEUTICALS, INC PURSUANT TO RULE 83 140 Scott Drive Menlo Park, California 94025 Tel: +1. |
|
| March 30, 2012 |
FIRST AMENDMENT COLLABORATION AGREEMENT First Amendment to Collaboration Agreement Exhibit 10.5 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. FIRST AMENDMENT TO COLLABORATION AGREEMENT This FIRST AMENDMENT (this “Amendment”) to the Collaboration Agreement dated as of January 28, |
|
| March 30, 2012 |
Offer Letter dated June 12, 2006, between Scott Borland and the Registrant Exhibit 10. |
|
| March 30, 2012 |
FIRST AMENDMENT LOAN AND SECURITY AGREEMENT Exhibit 10.3 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into this 28th day of October, 2008, by and among SILICON VALLEY BANK (“SVB”), OXFORD FINANCE CORPORATION (“Oxford”) and MAP PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”). SVB and Oxford are sometimes individually referred to as a “Lender”, and |
|
| March 30, 2012 |
AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT Amendment No. 1 to Common Stock Purchase Agreement Exhibit 10.37 AMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT This AMENDMENT NO. 1 (the “First Amendment”) to that certain Common Stock Purchase Agreement, dated November 11, 2009 (the “Agreement ”), by and between MAP Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Azimuth Opportunity Ltd., an international business company |
|
| March 30, 2012 |
FIRST AMENDMENT TO CHANGE IN CONTROL AGREEMENT First Amendment to Change in Control Agreement Exhibit 10.39 EXECUTION COPY FIRST AMENDMENT TO CHANGE IN CONTROL AGREEMENT This First Amendment to the Change in Control Agreement, dated February 6, 2012, is entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Thomas A. Armer, Ph.D (“Executive”). WHEREAS, Executive and the Company entered into that certain |
|
| March 30, 2012 |
FIFTH AMENDMENT TO LEASE AGREEMENT Exhibit 10.1 FIFTH AMENDMENT TO LEASE AGREEMENT This Fifth Amendment to Lease Agreement (this “Fifth Amendment”) is made as of November 1, 2011, by and between ARE-2425/2400/2450 GARCIA BAYSHORE, LLC, a Delaware limited liability company (“Landlord”), and MAP PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant entered into that certain Lease Agreement dated Ju |
|
| March 30, 2012 |
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT Second Amendment to Loan and Security Agreement Exhibit 10.4 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of April 5, 2011, by and among MAP PHARMACEUTICALS, INC, a Delaware corporation (“Borrower”), SILICON VALLEY BANK, a California bank (“SVB”) and OXFORD FINANCE CORPORATION, a Delaware corporation (“Ox |
|
| March 30, 2012 |
FOIA CONFIDENTIAL TREATMENT FOIA CONFIDENTIAL TREATMENT REQUESTED BY MAP PHARMACEUTICALS, INC PURSUANT TO RULE 83 March 30, 2012 140 Scott Drive Menlo Park, California 94025 Tel: +1. |
|
| March 30, 2012 |
Quarterly Report - AMENDMENT NO. 1 TO FORM 10-Q Amendment No. 1 to Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR TH |
|
| March 30, 2012 |
Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 30, 2012 |
FIRST AMENDMENT TO SEVERANCE AGREEMENT First Amendment to Severance Agreement Exhibit 10.40 EXECUTION COPY FIRST AMENDMENT TO SEVERANCE AGREEMENT This First Amendment to the Severance Agreement, dated February 1, 2012, is entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Timothy S. Nelson (“Executive”). WHEREAS, Executive and the Company entered into that certain Severance Agreement effectiv |
|
| March 30, 2012 |
Quarterly Report - AMENDMENT NO. 1 TO FORM 10-Q Amendment No. 1 to Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TR |
|
| March 30, 2012 |
Quarterly Report - AMENDMENT NO. 1 TO FORM 10-Q Amendment No. 1 to Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (MARK ONE) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRA |
|
| March 30, 2012 |
FIRST AMENDMENT TO CHANGE IN CONTROL AGREEMENT First Amendment to Change in Control Agreement Exhibit 10.38 EXECUTION COPY FIRST AMENDMENT TO CHANGE IN CONTROL AGREEMENT This First Amendment to the Change in Control Agreement, dated February 1, 2012, is entered into by and between MAP Pharmaceuticals, Inc., a Delaware corporation (“Company”), and Timothy S. Nelson (“Executive”). WHEREAS, Executive and the Company entered into that certain Chan |
|
| March 29, 2012 |
Current Report on Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2012 MAP PHARMACEUTICALS, INC. |
|
| March 29, 2012 |
MAP Pharmaceuticals Reports 2011 Fourth Quarter and Year End Financial Results Press Release Exhibit 99.1 MAP Pharmaceuticals Reports 2011 Fourth Quarter and Year End Financial Results MOUNTAIN VIEW, Calif., March 29, 2012 /PRNewswire/ —MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2011. The net loss for the fourth quarter ended December 31, 2011 was $13.8 million, compared to a net loss of $13.9 |
|
| March 29, 2012 |
Current Report on Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2012 MAP PHARMACEUTICALS, INC. |
|
| March 27, 2012 |
Press Release Exhibit 99.1 MAP Pharmaceuticals Receives Complete Response Letter from FDA for LEVADEX® (dihydroergotamine) NDA —No new clinical studies requested — — MAP Pharmaceuticals to Host Conference Call on Tuesday, March 27, 8:00 a.m. Eastern Time March 26, 2012 (MOUNTAIN VIEW, Calif.) — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that the United States Food and Drug Administra |
|
| March 27, 2012 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 d321452d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2012 MAP PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-33719 20-0507047 (State or Other Jurisdiction |
|
| March 16, 2012 |
Notification of Late Filing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 15, 2012 |
Correspondence February 14, 2012 Page 1 FOIA CONFIDENTIAL TREATMENT REQUESTED BY MAP PHARMACEUTICALS, INC. |
|
| February 14, 2012 |
MAPP / Map Pharmaceuticals, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: MAP Pharmaceuticals, Inc. Title of Class of Securities: Common Stock CUSIP Number: 56509R108 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b) N/A 3 |
|
| February 10, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* MAP Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 56509R108 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| January 27, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 25, 2012 MAP PHARMACEUTICALS, INC. |
|
| January 17, 2012 |
MAP Pharmaceuticals Appoints W. James O’Shea to Board of Directors Press Release Exhibit 99.1 MAP Pharmaceuticals Appoints W. James O’Shea to Board of Directors MOUNTAIN VIEW, Calif., Jan. 17, 2012 /PRNewswire/ — MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced the appointment of W. James O’Shea to its Board of Directors. Mr. O’ Shea brings to the Board 35 years of healthcare industry experience in product commercialization and operations. “We are privile |
|
| January 17, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2012 MAP PHARMACEUTICALS, INC. |
|
| December 2, 2011 |
SEC Response Letter FOIA CONFIDENTIAL TREATMENT REQUESTED 140 Scott Drive PURSUANT TO RULE 83 Menlo Park, California 94025 Tel: +1. |
|
| November 16, 2011 |
SEC Letter 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Abu Dhabi Moscow Barcelona Munich Beijing New Jersey Boston New York Brussels Orange County Chicago Paris Doha Riyadh November 16, 2011 Dubai Rome Frankfurt San Diego Hamburg San Francisco Hong Kong Shanghai VIA EDGAR Houston Silicon Valley London Singapore Securiti |
|
| October 7, 2011 |
Correspondence FOIA CONFIDENTIAL TREATMENT REQUESTED BY MAP PHARMACEUTICALS, INC. PURSUANT TO RULE 83 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Abu Dhabi Barcelona Beijing Boston Brussels Chicago Doha Dubai Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Moscow Munich New Jersey New York Orange Cou |
|
| September 23, 2011 |
Correspondence Letter 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Abu Dhabi Moscow Barcelona Munich Beijing New Jersey Boston New York Brussels Orange County Chicago Paris Doha Riyadh Dubai Rome Frankfurt San Diego Hamburg San Francisco Hong Kong Shanghai September 23, 2011 Houston Silicon Valley London Singapore VIA ED |
|
| August 12, 2011 |
CORRESP 1 filename1.htm FOIA CONFIDENTIAL TREATMENT REQUESTED BY MAP PHARMACEUTICALS, INC PURSUANT TO RULE 83 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com August 12, 2011 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 FIRM / AFFILIATE OFFICES Abu Dhabi Barcelona Beijing Bost |
|
| July 29, 2011 |
Correspondence Letter 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com July 29, 2011 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance FIRM / AFFILIATE OFFICES Abu Dhabi Moscow Barcelona Munich Beijing New Jersey Boston New York Brussels Orange County Chicago Paris Doha Riyadh Dubai Rome Frankfurt San Diego Hamburg San Fra |
